Allogene Therapeutics, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Election of Directors: Deborah Messemer

Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: Deborah Messemer”): 202,325,767 for, 26,099,641 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 62,586,527 for, 2,207,797 withheld, 98 abstained.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

Description as filed by funds: Election of Directors: Owen Witte, M.D.

Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: Owen Witte, M.D.”): 189,310,484 for, 39,114,924 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 53,952,168 for, 10,842,112 withheld, 142 abstained.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

Description as filed by funds: Election of Directors: Vicki Sato, Ph.D.

Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: Vicki Sato, Ph.D.”): 202,326,299 for, 26,099,109 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class II Directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 62,586,527 for, 2,207,797 withheld, 98 abstained.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

Description as filed by funds: To approve an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of common stock from 400,000,000 shares to 800,000,000 shares.

Allogene Therapeutics, Inc.’s own tally for this item (“4. Amendment to Amended and Restated Certificate of Incorporation To Increase the Number of Authorized Shares”): 221,767,995 for, 6,535,254 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Amendment to Amended and Restated Certificate of Incorporation To Increase the Number of Authorized Shares The Company's stockholders approved an amendment (the "Amendment") to the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares o…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 64,731,884 for, 62,538 against.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

Allogene Therapeutics, Inc.’s own tally for this item (“2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers”): 213,098,167 for, 11,951,256 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 50 managers: 63,442,227 for, 1,320,255 against, 31,939 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 147 managers: 129,709,789 for, 4,668,565 against, 2,923,431 abstained, 500 not voted, 39,947 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 50 managers: 132,144 for, 31,939 abstained, 64,404,333 1 year, 225,419 3 year, 588 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 140 managers: 18,837,403 for, 2,974,931 abstained, 500 not voted, 113,818,701 1 year, 284,578 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.

Allogene Therapeutics, Inc.’s own tally for this item (“5. Ratification of the Selection of Independent Registered Public Accounting Firm”): 282,022,884 for, 503,156 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 50 asset managers below reported 64,762,279 for, 216 against, 31,927 abstained.

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.